Loading...
•
Mar 31, 2023
TherapeuticsMD Q1 2023 Earnings Report
TherapeuticsMD reported a net loss from continuing operations and a decrease in license and service revenues due to business transformation to a royalty-based model.
Key Takeaways
TherapeuticsMD reported first quarter 2023 financial results, featuring a net loss from continuing operations of $2.3 million, or $0.24 per share, and license and service revenues of $0.4 million. The company's transition to a royalty-based business model led to decreased operating expenses and a focus on winding down commercial operations.
Net loss from continuing operations was $2.3 million, or $0.24 per share.
License and service revenues were $0.4 million.
Total operating expenses decreased by 82.8% to $3.1 million.
Net loss from discontinued operations was $1.3 million, or $0.13 per share.